What is Acerus Pharmaceuticals?
Acerus Pharmaceuticals Corporation, formerly Trimel Pharmaceuticals Corporation, is a specialty pharmaceutical company headquartered in Mississauga, Canada. Founded in 2008, the company is dedicated to the development, manufacture, marketing, and distribution of pharmaceutical products primarily focused on men's and women's health. Its product portfolio includes Natesto for testosterone replacement therapy and Noctiva for nocturia. Acerus is also advancing pipeline candidates such as Lidbree for vaginal pain and Stendra for erectile dysfunction, alongside exploring combination products and leveraging its TriVair technology platform for novel drug delivery. The company operates with a direct salesforce in the United States and Canada, complemented by an international distribution network.
How much funding has Acerus Pharmaceuticals raised?
Acerus Pharmaceuticals has raised a total of $24.5M across 2 funding rounds:
Debt
$6.5M
Share Placement
$18M
Debt (2019): $6.5M with participation from First Generation Capital
Share Placement (2020): $18M led by First Generation Capital
Key Investors in Acerus Pharmaceuticals
First Generation Capital
First Generation Capital is a venture capital firm that provides seed and early-stage investment capital to startup businesses. They focus on companies with the potential for social and sustainable impact, spanning sectors from social media to clean technology.
What's next for Acerus Pharmaceuticals?
The recent major strategic investment signals a pivotal growth phase for Acerus Pharmaceuticals. This capital infusion is expected to accelerate the commercialization of its existing product lines and advance its promising pipeline candidates through clinical development and regulatory approval. The company's focus on men's and women's health, coupled with its innovative delivery technologies, positions it for continued expansion within the competitive pharmaceutical market. Strategic partnerships and further financing rounds may be anticipated as Acerus aims to solidify its market presence and introduce new therapeutic solutions.
See full Acerus Pharmaceuticals company page
